Bayer agrees $10 billion-plus deal to put Monsanto Roundup litigation behind it

25 June 2020
bayer_large

German crop sciences and pharma major Bayer (BAYN: DE) has announced a series of agreements that will substantially resolve major outstanding Monsanto litigation, notably the US Roundup weedkiller product liability claims, that have plagued the company, as well as, dicamba drift litigation and PCB water litigation.

The news initially lifted the shares of Bayer, which acquired Monsanto in $63-billion deal in 2018, the stock was down 1.2% at 69.15 euros by early afternoon.

The main feature is the US Roundup resolution that will bring closure to approximately 75% of the current Roundup litigation involving around 125,000 filed and unfiled claims overall. The resolved claims include all plaintiff law firms leading the Roundup federal multi-district litigation (MDL) or the California bellwether cases, and those representing approximately 95% of the cases currently set for trial, and establish key values and parameters to guide the resolution of the remainder of the claims as negotiations advance. The resolution also puts in place a mechanism to resolve potential future claims efficiently.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical